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2011. We aimed to describe the distribution and susceptibility pattern of Candida species, and to evaluate risk factors for mortality in patients
with oncological (solid tumours) and haematological malignancies. Adults (16 years) with cancer were included in the present report.
Impact of therapeutic strategies on 7- and 30-day mortality were analysed by logistic regression, adjusting for propensity score by inverse
weighting probability of receiving early antifungal treatment and catheter removal. We included 238 (32.6%) patients (195 oncological, 43
haematological). Compared with oncological patients, haematological patients were more likely to have received chemotherapy (53.5%
versus 17.4%, p < 0.001) or corticosteroids (41.9% versus 21%, p < 0.001), and have neutropenia (44.2% versus 1.5%, p < 0.001).
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0.16–0.46). In conclusion, non-albicans species are emerging as the predominant isolates, particularly in haematological patients. Prompt,
adequate antifungal treatment plus catheter removal may lead to a reduction in mortality.
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491.e2 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIIntroductionCandidaemia is a severe fungal infection closely associated with
cancer and the complications of its treatment. Estimates of the
incidence of this infection vary substantially because surveil-
lance programmes in this population are scarce and most re-
ports are focused on haematological malignancies [1,2]. Despite
improvements in the management of patients with this condi-
tion and the introduction of echinocandins, candidaemia 30-day
mortality rates range from 35% to nearly 50% [2–5]. In addi-
tion, a shift towards an increasing prevalence of non-albicans
species with potentially decreased ﬂuconazole susceptibility has
been reported [6,7]. Unfortunately, there is less related infor-
mation in patients with solid tumours, but it appears that the
species isolated in oncological patients are similar to those in
the general population [4,8].
In this study, we present episodes of candidaemia occurring
in cancer patients by analysing data from a prospective
population-based surveillance in Spain (CANDIPOP study). We
aim to describe Candida species distribution and antifungal drug
resistance in patients with underlying malignancies, to update
the prognosis of Candida bloodstream infections (BSI) in the
oncological and haematological population, and particularly, to
assess the impact of therapeutic strategies on mortality.Material and methodsStudy design, setting and patients
The CANDIPOP study was a prospective, population-based
surveillance for Candida BSI conducted from May 2010 to April
2011 in 29 hospitals located in ﬁve metropolitan areas of Spain.
The study methods were described previously [9]. Brieﬂy, case
reporting was laboratory-based. Each candidaemia episode was
reported to regional study collaborators who collected the
clinical data and recorded the 30-day follow-up outcome (i.e.
survival or death). Patient management and antifungal prophy-
laxis policy was at the discretion of the attending physician.
Candida isolates were sent to the Mycology Reference Labora-
tory at the National Centre for Microbiology in Madrid, Spain,
for species conﬁrmation and antifungal susceptibility testing.
Species were identiﬁed by sequencing the internal transcribed
spacer regions 1 and 2 from ribosomal DNA. Susceptibility to
antifungal drugs was assessed according to the protocols [10,11]
and clinical breakpoints of the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) (Clinical breakpoints-
fungi, Table v 6.1. Available at: http://www.eucast.org/clinical
breakpoints/, accessed 1 May 2013). The study protocol was
approved by the ethics committees of the participating centres.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectThis report focuses on Candida BSI episodes in adult patients
(16 years) with underlying solid organ tumours or haemato-
logical malignancies. Patients who had not received treatment
for oncological/haematological disease within the previous
12 months were excluded. Only the ﬁrst episode of candi-
daemia per patient was included. All patients provided written
informed consent for participation.
Deﬁnitions
The deﬁnitions have been reported elsewhere [9,12]. In sum-
mary, proven catheter-related candidaemia was deﬁned as fol-
lows: 1) evidence of catheter exit site exudate with the same
Candida spp. that was isolated from the bloodstream; 2) semi-
quantitative culture of the catheter tip yielded >15 CFU of the
same Candida spp.; or 3) simultaneously quantitative cultures of
blood samples showed a ratio of 3:1 of CFU between blood
samples obtained through the catheter and a peripheral vein, or
the differential time to positivity was 2 hours for non-glabrata
Candida BSI [13,14]. Secondary foci required identiﬁcation of
the same Candida species at the affected site. Episodes with no
deﬁned secondary source or without proven catheter-related
origin were classiﬁed as primary. Breakthrough candidaemia
was established on detection of Candida BSI in patients who had
been receiving antifungal drugs for >3 days. Neutropenia was
described as granulocyte count <500 cell/mm3 at time of ﬁrst
positive Candida species blood culture collection. Severity of
illness was measured by the Acute Physiology and Chronic
Health Evaluation (APACHE) II score for patients admitted to
the Intensive Care Unit (ICU) and the Pitt bacteraemia score on
the day of candidaemia [15,16]. Adequate antifungal treatment
was deﬁned as use of the correct dose of antifungal agent for a
susceptible Candida isolate. Appropriate ﬂuconazole dosing was
6 mg/kg/day (adjusted for renal function if necessary) except for
non-susceptible Candida spp., Candida glabrata, Candida guillier-
mondii and Candida krusei, which was considered inappropriate
(see Supporting information, Table S1). Early central venous
catheter (CVC) removal was established when the line was
removed within 48 hours of the incident BSI, and in patients
with multiple CVCs, when at least the responsible CVC was
removed within this timeframe.
Statistical analysis
Categorical data are expressed as the count and percentage,
and numerical data as the median and interquartile range.
Categorical variables were compared with the chi-squared or
Fisher exact test, and continuous variables with the Mann–
Whitney U-test. All statistical tests were two-tailed, and sig-
niﬁcance was set at p < 0.05.
Logistic regression analysis was applied to identify predictive
factors of 7-day and 30-day mortality. As our aim was toious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 491.e1–491.e10
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of care in candidaemia—use of adequate antifungal agents and
catheter removal—only patients with a CVC in place at can-
didaemia onset were included in this analysis. The reason for
choosing 7-day mortality as a primary endpoint for multivariate
analysis was based on the hypothesis that it would adequately
represent the impact of therapies in patients with an intrinsi-
cally high risk of death due to their comorbidities [7,17]. Var-
iables with p values <0.2 in the univariate analysis and
considered clinically relevant underwent multivariate analysis.
Therapies were maintained in the ﬁnal model as a ﬁxed variable.
To limit confounding by patient’s pretreatment characteristics,
the method of adjustment used was the inverse probability of
receiving appropriate combined treatment (CVC removal and
antifungal treatment) weighting, on the basis of estimated
propensity scores. The propensity score, inverse probability of
early implementation of therapeutic strategies, was calculated
using multivariate logistic regression model and included the
following variables: host factors and baseline comorbidities
(Charlson index, age and neutropenia), severity of illness
(APACHE-II score and Pitt score), clinical features of candi-
daemia onset (septic shock and breakthrough candidaemia) and
factors that might have inﬂuenced prompt CVC removal
(presence of long-term CVC, renal replacement therapy and
parenteral nutrition). Statistical analyses were performed with
STATA software package (version 13.1, Stata Corp, College
Station, TX, USA).ResultsOver the study period, 773 episodes of Candida BSI were
detected. Twenty-one patients were excluded because they did
not agree to participate, leaving 752 episodes in 729 patients in
the overall CANDIPOP study. Among them, 238 (32.6%)
incident episodes of candidaemia in adults with cancer were
analysed in the present report: 195 (82%) in patients with solid
organ tumours (oncological patients) and 43 (18%) in patients
with haematological malignancies.
Patient characteristics
The epidemiological and clinical characteristics of the patients
are outlined in Table 1. Most cases involved patients with an
active underlying cancer (i.e. newly diagnosed or relapsing/
resistant malignancy). Compared with oncological patients,
haematological patients were more likely to have received
chemotherapy or corticosteroids, and have neutropenia or
mucositis at candidaemia onset. Presence of a long-term CVC
was also more frequent in the haematological population.
Oncological patients were older and more likely to haveClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infreceived parenteral nutrition or undergone surgery within the
previous 3 months than haematological patients.
Candida species and antifungal susceptibility testing
The distribution of Candida species is shown in Table 1. Overall,
Candida albicans was the most common isolate (101 of 243,
41.6%), followed by Candida parapsilosis (47, 19.3%), C. glabrata
(43, 17.7%), Candida tropicalis (25, 10.3%), C. krusei (7, 2.9%),
C. guilliermondii (6, 2.5%) and others (14, 5.8%). Candidaemia
was predominantly caused by non-albicans species in both
haematological (32 of 45 strains, 71.1%) and oncological (110 of
198 strains, 55.6%) patients.
Sixty-seven of 243 (27.6%) Candida isolates were non-
susceptible to ﬂuconazole. Speciﬁcally, 57 (85.1%) of these
strains were isolates belonging to species with reduced sus-
ceptibility to ﬂuconazole (C. glabrata, Candida nivariensis,
C. guilliermondii and C. krusei). Only 1% of C. albicans (1/101) and
4% of C. parapsilosis (2/47) were intermediate or resistant to
ﬂuconazole (MIC  4 mg/L) (see Supporting information,
Table S2). Interestingly, the rate of ﬂuconazole non-susceptible
isolates was similar in haematological and oncological patients
(13/45 (28.9%) versus 54/198 (27.3%), p 0.83). Resistance to
one or more echinocandins was uncommon (one C. tropicalis
and one C. glabrata), and was associated with FKS1 and FKS2
gene alterations, respectively [18]. A single Candida kefyr strain
was resistant to amphotericin B.
Clinical data
Catheter-related candidaemia was the most frequent estab-
lished source of infection in both oncological and haemato-
logical patients (36.4% and 37.2%, respectively).
Haematogenous dissemination of Candida spp. was reported in
18 (7.6%) patients, two of whom had multiple metastatic in-
fections: ocular candidiasis 11, skin lesions four, endocarditis
three, and liver and lung involvement, one each. Cutaneous
metastatic foci were only observed in neutropenic haemato-
logical patients.
Of 237 patients with available information, 35 (14.8%) had
breakthrough candidaemia that occurred while they were
receiving azoles (27, 11.4%) (mainly ﬂuconazole in 20), echi-
nocandins (6, 2.5%), or amphotericin B (2, 0.8%). These epi-
sodes were diagnosed after a median of 11 days (interquartile
range 8–14) of antifungal exposure. Because of its potential
relevance and differential features, breakthrough candidaemia is
compared with non-breakthrough cases in Table 2.
Therapeutic measures
Therapeutic measures are detailed in Table 3. Overall, 217
(91.2%) patients received targeted antifungal treatment for
candidaemia. Echinocandins in monotherapy were used moreectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 491.e1–491.e10
TABLE 1. Main demographic and clinical characteristics of 238 adult patients with candidaemia and cancer
Characteristics
Underlying cancer
p-valueHaematological malignancya (n [ 43) Solid organ tumour (n [ 195)
Demographics
Median age, years 62.2 (50.9–70.8) 69.4 (60.2–76.7) <0.001
Male sex 21 (48.8) 121 (62.1) 0.110
Outpatient b – 23 (11.8) 0.018
Days in hospital until Candida BSI 18 (10–36) 22 (14–40) 0.137
Charlson index 2 (2–4) 3 (2–4) 0.194
In ICU at diagnosis 7 (16.3) 33 (16.9) 0.919
APACHE II score 22 (18–29) 19 (15–23) 0.175
Comorbidities
Diabetes mellitus 5 (11.6) 47 (24.1) 0.073
Chronic obstructive pulmonary disease 4 (9.3) 29 (14.9) 0.339
Chronic renal failure – 16 (8.2) 0.084
HIV infection 4 (9.3) 3 (1.5) 0.022
Liver cirrhosis – 5 (2.6) 0.588
Underlying malignancy status
Newly diagnosed cancer 18 (41.9) 102 (52.3) 0.215
Relapsing cancer 6 (14) 27 (13.8) 0.985
Progressive/resistant tumour or partial remission 11 (25.6) 47 (24.1) 0.838
Complete response or stable disease 8 (18.6) 14 (7.2) 0.035
Othersc – 5 (2.6) 0.588
Risk factors for candidaemia
Prior antibiotic therapy 42 (97.7) 186/194 (95.9) 1.000
Anti-anaerobic agentsd 36 (83.7%) 164/194 (84.5) 0.894
CVC placement 37 (86) 156 (80) 0.359
Long-term CVCe 21 (48.8) 36 (18.5) <0.001
Surgery (<3 months) 5 (11.6) 140 (71.8) <0.001
Abdominal surgery 4 (9.3) 92 (47.2) <0.001
TPN 16 (37.2) 109 (55.9) 0.026
Intubation at diagnosis 3 (7.0) 26 (13.3) 0.249
Prior RRTf 2 (4.7) 8 (4.1) 1.000
Prior Candida spp. colonization 10 (23.3) 68/194 (35.1) 0.136
Prior antifungal exposure 20 (46.5) 37/194 (19.1) <0.001
Equinocandins 8 (18.6) 5/193 (2.6) <0.001
Azoles 15 (34.9) 32/193 (16.6) 0.007
Previous corticosteroidsg 18 (41.9) 41 (21) 0.004
Chemotherapy 23 (53.5) 34 (17.4) <0.001
Neutropenia 19 (44.2) 3 (1.5) <0.001
Mucositis at diagnosis 12/41 (29.3) 9/194 (4.6) <0.001
Source of infection
Primary 26 (60.5) 99 (50.8) 0.249
Catheter-relatedh 16 (37.2) 71 (36.4) 0.922
Abdominal source 1 (2.3) 10 (5.1) 0.694
Urological tract – 13 (6.7) 0.133
Others – 2 (1) 1.000
Clinical features
Pitt bacteraemia score at onset 2 (1–4) 1 (0–3) 0.091
Septic shock at onset 4 (9.3) 24 (12.3) 0.580
Bacteria in incident blood culture 6 (14) 40 (20.5) 0.324
Disseminated infection 6 (14) 12 (6.2) 0.106
Candida speciesi
C. albicans 13/45 (28.9) 88/198 (44.4) 0.056
C. parapsilosis 6/45 (13.3) 41/198 (20.7) 0.258
C. tropicalis 10/45 (22.2) 15/198 (7.6) 0.011
C. glabrata 5/45 (11.1) 38/198 (19.2) 0.200
C. krusei 2/45 (4.4) 5/198 (2.5) 0.617
C. guilliermondii 2/45 (4.4) 4/198 (2) 0.308
Othersj 7/45 (15.6) 7/198 (3.5) 0.006
Values are reported as no./total no. (%) or median (interquartile range) unless otherwise indicated. Previous use of antibiotics, antifungal exposure, corticosteroids and
chemotherapy refers to within the previous month before the ﬁrst positive blood culture.
Abbreviations: BSI, bloodstream infection; ICU, intensive care unit; HIV, human immunodeﬁciency virus; CVC, central venous catheter; TPN, total parenteral nutrition; RRT, renal
replacement therapy.
aThe haematological disease was leukaemia in 26, lymphoma in 16, and multiple myeloma in one patient. Among them, nine were haematological transplant recipients.
bCandidaemias detected 2 days after hospitalization.
cPalliative treatment in two, unknown tumour staging in three.
dInclude β-lactam/β-lactamase inhibitor, carbapenems, metronidazole and clindamycin.
eInclude skin-tunnelled catheters and totally implantable catheters.
fPeritoneal dialysis, haemodialysis or haemodiaﬁltration.
g>10 mg of systemic methylprednisolone per day (or equivalent) during 5 days.
hCatheter-related candidaemia was diagnosed according to the following deﬁnition criteria: positive semi-quantitative tip culture in 76 (87.4%) patients, differential time to positivity
in 9 (10.3%) patients without C. glabrata bloodstream infection, and differential quantitative blood cultures showing a ratio 3 : 1 of CFU in 2 (2.3%) patients.
iCandida species distribution among 243 isolates. Include ﬁve episodes of mixed candidaemias caused by two Candida species (three in oncological patients and two in haematological
patients).
jOthers include C. lusitaniae (3), C. lypolitica (3), C. kefyr (2), C. dubliniensis (2), C. metapsilosis (1), C. orthopsilosis (1), C. nivariensis (1), and Pichia anomala (1).
491.e4 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIoften as ﬁrst-line therapy in haematological patients (41.9%
versus 26.2%, p 0.040), whereas oncological patients were
more likely to receive azoles (60% versus 27.9%, p < 0.001). InClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectnon-breakthrough cases, treatment was started at a median
time of 2 days (interquartile range 1–3) after the incident blood
culture. Of particular note, 106 patients (44.5%) did not receiveious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 491.e1–491.e10
TABLE 2. Characteristics and outcome of cancer patients with breakthrough and non-breakthrough candidaemia
Characteristics Breakthrough (n [ 35) Non-breakthrough (n [ 202) p-value
Demographics
Median age, years 64.1 (52.0–71.8) 68.8 (58.7–76.1) 0.014
Male sex 20 (57.1) 122 (60.4) 0.717
Days in hospital until Candida BSIa 29 (17.5–40.3) 20 (12.8–40) 0.057
Underlying cancer
Solid tumour 19 (54.3) 175 (86.6) <0.001
Leukaemia 15 (42.9) 11 (5.4) <0.001
Lymphoma/myeloma 1 (2.9) 16 (7.9) 0.480
Haematological transplant recipient 5 (14.3) 4 (2) 0.004
Risk factors for candidaemia
Prior antibiotic therapy 35 (100) 192/201 (95.5) 0.363
Anti-anaerobic agentsb 33 (94.3) 166/201 (82.6) 0.079
CVC placement 33 (94.3) 159 (78.7) 0.030
Long-term CVC 13 (37.1) 44 (21.8) 0.050
TPN 21 (60) 103 (51) 0.324
Previous corticosteroids 9 (25.7) 49 (24.3) 0.853
Previous Candida spp. colonization 9 (25.7) 69/201 (34.3) 0.317
Digestive tract colonization 4 (11.4) 11/201 (5.5) 0.248
Chemotherapy 16 (45.7) 41 (20.3) 0.001
Neutropenia 13 (37.1) 9 (4.5) <0.001
Mucositis at diagnosis 9/34 (26.5) 12/200 (6) 0.001
Source of infection
Primary 17 (48.6) 108 (53.5) 0.592
Catheter-related 15 (42.9) 71 (35.1) 0.381
Candida species
C. albicans 9 (25.7) 88 (43.6) 0.047
C. parapsilosis 8 (22.9) 37 (18.3) 0.527
C. glabrata 8 (22.9) 32 (15.8) 0.306
C. tropicalis 2 (5.7) 22 (10.9) 0.545
C. krusei 3 (8.6) 3 (1.5) 0.043
Mixed fungaemia – 5 (2.5) 1.000
Fluconazole non-susceptible isolate 14 (40) 52 (25.7) 0.082
Clinical features
Septic shock at onset 4 (11.4) 24 (11.9) 1.000
Disseminated infection 5 (14.3) 13 (6.4) 0.156
7-day mortality 5 (14.3) 24 (11.9) 0.779
30-day mortality 12 (34.3) 63 (31.2) 0.716
Values are reported as no./total no. (%) or median (interquartile range) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; CVC, central venous catheter; TPN, total parenteral nutrition.
aOnly includes nosocomial candidaemias, cases with positive blood culture after 2 days of hospitalization.
bInclude β-lactam/β-lactamase inhibitor, carbapenems, metronidazole and clindamycin.
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blood sampling; 58 of them (54.7%) due to a delay in starting
therapy.
Early catheter removal (48 h) was performed in 46.8% of
episodes (89 of 190 patients with available data). Nevertheless,TABLE 3. Therapeutic measures and outcomes of patients by unde
Overall
(n [ 238)
Ha
m
Initial antifungal agent
Azole 129 (54.2) 12
Echinocandin 69 (29) 18
Amphotericin B 12 (5) 5 (
Combination 7 (2.9) 4 (
No targeted antifungal treatment 21 (8.8) 4 (
Therapeutic measures (£48 h)
CVC removala 89/190 (46.8) 11
Adequate antifungal therapy 132/238 (55.5) 28
Clinical response and outcome
Persistent candidaemiab 49/151 (32.5) 10
Drug-related toxicity 8 (3.4) 6 (
Median days of treatmentc 20 (15–28) 23
Median time to death 11 (3–18) 11
7-day mortality 29 (12.2) 5 (
30-day mortality 75 (31.5) 13
Values are reported as no./total no. (%) or median (interquartile range) unless otherwise in
Abbreviation: CVC, central venous catheter.
aData concerning time of CVC removal were missing for three patients.
bAnalysis performed in the subset of patients with follow-up blood cultures 3 days after in
cAmong 30-day survivors (n = 163).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infhaematological patients were less likely to undergo catheter
removal in a timely manner.
Follow-up blood cultures were obtained in 66.8% (151/226)
of patients who survived >48 hours, and persistent candidaemia
for >3 days after incident culture was documented in 32.5%rlying malignancy
ematological
alignancy (n [ 43)
Solid tumour
(n [ 195)
p-
value
(27.9) 117 (60) <0.001
(41.9) 51 (26.2) 0.040
11.6) 7 (3.6) 0.045
9.3) 3 (1.5) 0.022
9.3) 17 (8.7) 1.000
/37 (29.7) 78/153 (51) 0.020
/43 (65.1) 104/195 (53.3) 0.159
/30 (33.3) 39/121 (32.2) 0.908
14) 2 (1) 0.001
.5 (17.0–35.5) 19 (15.0–26.3) 0.048
(3–17.5) 10.5 (4–18) 0.910
11.6) 24 (12.3) 0.902
(30.2) 62 (31.8) 0.842
dicated.
cident blood culture (n = 151).
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 491.e1–491.e10
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the subset of patients with CVCs, persistent candidaemia was
less frequent in those treated with adequate antifungals (48 h)
and early CVC removal than in those in whom both therapeutic
strategies were not implemented (25% (11/44) versus 44.3%
(39/88), p 0.031).
Outcome and predictors of mortality
Cumulative mortality was 12.2% at day 7 and 31.5% at day 30,
with no signiﬁcant differences between oncological and hae-
matological patients. Variables associated with 7-day mortality
are described in Table 4. On multivariate analysis, and after
including the propensity score adjustment, combined treatment
(CVC removal plus antifungal therapy) within the ﬁrst 48 hours
was independently associated with 7-day mortality (adjusted
OR 0.05; 95% CI 0.01–0.42). Inclusion of speciﬁc sources of
the infection (primary candidaemia or catheter-related candi-
daemia) in the ﬁnal multivariate model did not signiﬁcantly
change the impact of adequate combined treatment (data not
shown). To further assess the impact of therapeutic strategies
at a later time point, variables potentially associated with 30-
day-mortality were analysed (see Supporting information,TABLE 4. Univariate and multivariate logistic regression analyses of
patients with CVC in place at candidaemia diagnosis
Variable Alive (n [ 171) Died (n [ 22)
Host factors
Age, years 66.7 (56.9–75.0) 64.3 (55.2–75.2)
Charlson index 2 (2–4) 2 (2–6)
In ICU at diagnosis 34 (19.9) 4 (18.2)
Solid tumour 138 (80.7) 18 (81.8)
Haematological transplant recipient 8 (4.7) 0 (-)
Newly diagnosed cancer 84 (49.1) 13 (59.1)
HIV infection 4 (2.3) 1 (4.5)
Neutropenia 18 (10.5) 3 (13.6)
Previous surgery (<3 months) 105 (61.4) 14 (63.6)
Chemotherapy (<1 month) 41 (24) 7 (31.8)
Previous RRT 8 (4.7) 2 (9.1)
Intubation 25 (14.6) 3 (13.6)
Long term CVC 53 (31) 4 (18.4)
Clinical data
Primary source 79 (46.2) 15 (68.2)
Catheter-related 80 (46.8) 6 (27.3)
Secondary sourceb 12 (7) 1 (4.5)
Breakthrough candidaemia 29/170 (17.1) 4 (18.2)
Septic shock 16 (9.4) 7 (31.8)
Bacteria in incident culture 30 (17.5) 5 (22.7)
Candida species
C. albicans 71 (41.5) 8 (36.4)
C. parapsilosis 40 (23.4) 4 (18.2)
C. glabrata 32 (18.7) 2 (9.1)
C. tropicalis 13 (7.6) 4 (18.2)
C. krusei 4 (2.3) 1 (4.5)
Fluconazole non-susceptible isolates 48 (28.1) 5 (22.7)
Therapeutic measures (£48 h)
Adequate antifungal treatment 106 (62) 11 (50)
CVC removalc 85/168 (50.6) 4 (18.2)
Adequate combined treatmente 61/168 (36.3) 1 (4.5)
Values are reported as no./total no. (%) or median (interquartile range) unless otherwise in
Abbreviations: BSI, bloodstream infection; CVC, central venous catheter; HIV, human immu
aMultivariate analysis is adjusted by using a propensity score inverse weighting probability of
bSecondary source refers to abdominal, urologic or other non-catheter-related origins of ca
cData concerning time when CVC was removed were missing in three patients.
eAdequate antifungal treatment in addition to CVC removal.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectTable S3). On propensity score adjusted multivariate analysis,
combined treatment still remained associated with lower 30-
day mortality (adjusted OR 0.27; 95% CI 0.16–0.46), while
primary source of candidaemia (adjusted OR 3.47; 95% CI
2.05–5.89) and C. krusei (adjusted OR 12.59; 95% CI
2.46–64.48) were added as prognostic factors. Finally, because
inclusion of patients who died early in the course of candi-
daemia—before they could undergo CVC removal or receive
antifungal treatment—might have introduced a bias favouring
the association between therapeutic measures and lower odds
of mortality, a separate multivariate analysis was performed to
account for this possibility. After excluding patients who died
within the ﬁrst 48 hours of candidaemia onset (n = 9), the
beneﬁt of prompt antifungal therapy together with catheter
removal on 30-day mortality remained stable (adjusted OR
0.34; 95% CI 0.20–0.59).DiscussionThe present report constitutes the largest population-based
surveillance for candidaemia performed in cancer patients inprognostic factors for early mortality (0–7 days) in 193 cancer
Univariate analysis Multivariate analysisa
OR (95% CI) p value Adjusted OR (95% CI) p value
1.00 (0.97–1.03) 0.931
1.26 (1.03–1.54) 0.024 1.15 (0.89–1.48) 0.274
0.90 (0.28–2.82) 0.850
1.08 (0.34–3.39) 0.900
– –
1.50 (0.61–3.68) 0.381
1.99 (0.21–18.63) 0.547
1.34 (0.36–4.98) 0.660
1.10 (0.44–2.77) 0.839
1.48 (0.56–3.88) 0.425
2.04 (0.40–10.27) 0.388
0.92 (0.25–3.35) 0.902
0.49 (0.16–1.53) 0.223
2.50 (0.97–6.43) 0.058 3.64 (1.11–11.90) 0.033
0.43 (0.16–1.14) 0.090
0.63 (0.08–5.10) 0.666
1.08 (0.34–3.43) 0.895
4.52 (1.61–12.72) 0.004 3.27 (0.75–14.16) 0.114
1.38 (0.47–4.04) 0.554
0.80 (0.32–2.02) 0.644
0.73 (0.23–2.28) 0.585
0.43 (0.10–1.95) 0.277
2.70 (0.80–9.17) 0.111
1.99 (0.21–18.63) 0.547
0.75 (0.26–2.16) 0.598
0.61 (0.25–1.50) 0.282
0.22 (0.07–0.67) 0.008
0.08 (0.01–0.64) 0.017 0.05 (0.01–0.42) 0.006
dicated.
nodeﬁciency virus; ICU, intensive care unit; RRT, renal replacement therapy.
receiving adequate combined treatment.
ndidaemia.
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epidemiology and management of candidaemia in patients with
underlying malignancies.
Although the shift to non-albicans Candida species is a cause
of concern for clinicians, the predominance of these species in
cancer patients has been the rule worldwide [2,3,6,8]. The
lower percentage C. albicans in haematological patients may be
partially explained by the widespread prophylactic use of azoles
[6,7,19,20]. However, other factors such as geographical dif-
ferences and institution-speciﬁc variables may contribute to the
epidemiology. In this line, and in keeping with previous reports,
we found that the most common non-albicans species in hae-
matological patients was C. tropicalis [3,21]. In contrast, but in
agreement with the epidemiology described in the overall
population of Southern Europe and Latin America [5,22,23],
C. parapsilosis and C. glabrata were the predominant non-albicans
species in oncological malignancies.
Not surprisingly, a higher percentage of haematological than
oncological patients had recent azole exposure. However,
similar rates of non-susceptible strains (around 28%) were
found in both populations. These ﬁndings may reﬂect the in-
ﬂuence of other variables, apart from antifungal drug exposure,
in selecting non-susceptible strains (e.g. suboptimal dosing or
length of previous antifungal exposure [4,24] and different
exposure to antibacterial compounds [25]). In addition, we
observed that resistance rates to echinocandins in non-para-
psilosis isolates were negligible. Unfortunately, there is no
updated information in cancer patients to compare our results,
but in general, surveillance programmes have described low
resistance to echinocandins [26,27]. However, further studies
are needed because the increasing use of these antifungals can
lead to higher percentages of resistant isolates [28].
Regarding breakthrough candidaemia, our data conﬁrm that
multiple factors might be involved. First, breakthrough infection
was more likely in patients with leukaemia, neutropenia, or
disruption of mucosal barriers, such as mucositis. These ﬁnd-
ings suggest that translocation from the gastrointestinal tract
may be a major factor in breakthrough candidaemia. Second,
breakthrough cases were often caused by ﬂuconazole non-
susceptible isolates, especially C. krusei. This might reﬂect fail-
ure of azole prophylaxis or emergence of azole-resistant spe-
cies from the gastrointestinal tract due to changes in the
patient’s colonization. However, it should be noted that
breakthrough candidaemia also occurred in patients receiving
echinocandins, and included susceptible isolates such as
C. parapsilosis. This suggests that an exogenous source of
infection such as CVCs also contributes to some breakthrough
cases.
All-cause 30-day mortality in the present cohort remained
high (30.9%) and did not differ between oncological andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infhaematological patients. However, mortality in these pop-
ulations often results from conditions apparently unrelated to
candidaemia, such as the baseline underlying disease [8]. In our
multivariate analysis of risk factors for 7-day and 30-day mor-
tality, catheter removal together with adequate antifungal
treatment within the ﬁrst 48 hours after candidaemia onset
were protective factors. Although these results are consistent
with American and European guidelines [29,30], some aspects
should be highlighted. First, our ﬁndings cannot be generalized
to the entire neutropenic population, because only 6.3% of
patients analysed had neutropenia. As a rule, this subgroup of
patients has been poorly represented in previous studies that
have assessed the inﬂuence of CVC removal on the prognosis
of candidaemia [31]. Hence, future evaluations are needed to
facilitate a rational approach of CVC management in this spe-
ciﬁc population. Second, prompt CVC removal is not always
feasible because of certain cancer-related factors and because it
may not be possible to insert a new line. Hence, there is no
clear consensus on how to handle long-term CVCs in cancer
patients. Unfortunately our study was not designed to elucidate
this particular issue. Third, catheter removal is especially
desirable in cases of C. parapsilosis because this species is
associated with intravascular device infection [32,33]. This
point is of special interest, because contemporary reports have
detected a rise in C. parapsilosis BSI [3,8]. This ﬁnding may be
inﬂuenced by local epidemiology, but it might also be related to
the increasing use of echinocandins [34] combined with higher
percentages of CVC-related candidaemia in haematological
patients [2]. In the present study, the percentage of proven
CVC-related candidaemia was similar in both oncological and
haematological patients (37.2% versus 36.4%, respectively), and
it increased when only the subset of breakthrough candidae-
mias was considered (42.9%). Taken as a whole, these data
suggest that all catheters should be investigated as a potential
focus of infection regardless of the underlying malignancy, and
that a targeted CVC removal strategy should be carefully
evaluated on an individual basis.
This study has some limitations. First, although the overall
CANDIPOP study was a population-based surveillance, we lack
general data on the number of patients with underlying malig-
nancies who were at risk for candidaemia during the study
period, precluding the calculation of candidaemia incidence
rates in cancer patients. Second, management policies for
cancer patients may not have been homogeneous, which limits
the ability to generalize our results to other areas. Third,
because a signiﬁcant number of our patients received different
antifungal agents for the treatment of their candidaemia
episode, no further analysis was performed on the impact of
each antifungal drug class on outcome. Finally, the precise
number of disseminated candidiasis remains undeﬁned becauseectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 491.e1–491.e10
491.e8 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIof the observational nature of the study and lack of systematic
diagnostic procedures.
In conclusion, 27.6% of Candida isolates in Spain were non-
susceptible to ﬂuconazole, indicating that updated local epide-
miological studies are needed to guide empirical antifungal
therapy. Catheter removal within 48 hours after candidaemia
and adequate antifungal treatment may lead to a reduction in
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